AI assistant
AGENUS INC — Director's Dealing 2012
Jan 31, 2012
34023_dirs_2012-01-31_e4881b0c-2ba7-4be0-a75c-8d78cd4db9f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGENUS INC (agen)
CIK: 0001098972
Period of Report: 2012-01-26
Reporting Person: ARMEN GARO H (Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-01-26 | Common Stock | A | 1389 | $2.76 | Acquired | 933681 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 831142 | Indirect |
Footnotes
F1: Respresents the settlement of restricted stock granted on January 26, 2010.
F2: Dr. Armen is trustee and has investment authority for the Garo Armen 2009 2 Year GRAT and the Garo Armen 2009 4 Year GRAT, each holding 211,850 and 363,969 shares of Agenus Inc. common stock, respectively. Dr. Armen disclaims beneficial ownership therein. Dr. Armen is the General Partner of Armen Partners LP. As of the date of this report Armen Partners owns a total of 251,277 shares of Agenus Inc. common stock. Dr. Armen is also CEO, Chairman of the Board of Managers and a member of Antigenics Holdings LLC, ("Holdings") which, as of the date of this report, owns 4,046 shares of Agenus Inc. comon stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Armen Partners and Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.